Citations

Clear

119 citation(s) found for "Sheehan, J".

Radiosurgery for Sporadic Facial Nerve Schwannoma: An International Multi-institutional Study of 60 Cases
Marinelli, John P. , Lloyd, Simon , Steiner, Nejc , Babajanian, Eric E. , Lohse, Christine M. , Sheehan, Jason , Kutz, Joe Walter , Duke, Simon, Link, Michael J., Carlson, Matthew L. , Cottrell, Justin , Borsetto, Daniele , Mantziaris, Georgios , Meng, Ying , Axon, Patrick , Kondziolka, Douglas , Roland, J. Thomas

Mayo Clinic

Otology & Neurotology | November 13, 2025 | Volume: 47 | Issue: 2 | Pages: 350-355

10.1097/mao.0000000000004758 | PMID 41225703 Get It

Objective: To characterize patient outcomes after primary stereotactic radiosurgery (SRS) for the management of sporadic facial nerve schwannoma. Study design: Retrospective cohort study. Setting: Six tertiary referral centers across the United States and United Kingdom. Patients: Adults undergoing SRS from 2000 through 2023 for sporadic facial nerve schwannoma along any segment of the facial nerve were included. Patients with NF2-related schwannomatosis were excluded. Intervention: Stereotactic radiosurgery. Main outcome measure: Long-term tumor control. Results: Among 60 patients meeting inclusion, the median age at SRS was 52 years (IQR: 41 to 64) with a median tumor size of 19.5 mm (IQR: 14.7 to 22.8). Tumors commonly involved the internal auditory canal (73%), cisternal (49%), geniculate/labyrinthine (47%), and tympanic segments (22%). Two patients experienced SRS failure and underwent salvage treatment; salvage-free survival rates (95% CI; number still at risk) at 1, 3, 5, and 10 years after SRS were 100% (100 to 100; 55), 100% (100 to 100; 36), 100% (100 to 100; 18), and 87% (72 to 100; 9), respectively. Among 31 (52%) patients with House-Brackmann (HB) grade I facial function at presentation, only 6 demonstrated worse facial function at a median of 3.2 years (IQR: 1.7 to 6.6) after SRS. Of 18 patients with serviceable hearing (AAO-HNS class A/B) at SRS, 13 maintained serviceable hearing at a median of 1.0 years (IQR: 0.5 to 4.9) of post-SRS audiometric follow-up. Conclusions: Durable tumor control after primary SRS for sporadic facial nerve schwannoma is achieved in most patients. Among those with HB grade I facial function at presentation, treatment with SRS harbors limited additional risk of facial paresis beyond observation alone.
Standalone Endovascular Embolization versus Stereotactic Radiosurgery in the Treatment of Arteriovenous Malformations in Eloquent Brain
Musmar, Basel , Abdalrazeq, Hammam , Adeeb, Nimer , Salim, Hamza , Roy, Joanna M. , Aslan, Assala , Tjoumakaris, Stavropoula I., Ogilvy, Christopher S. , Başkaya, Mustafa K. , Kondziolka, Douglas, Sheehan, Jason P. , Riina, Howard A. , Abushehab, Abdallah, Naamani, Kareem El, Ironside, Natasha , Gummadi, Sanjeev, Ataoglu, Cagdas , Muram, Sandeep , Sconzo, Daniel , Rezai, Arwin, Alwakaa, Omar , Park, Min S. , Hanalıoğlu, Şahin , Erginoğlu, Ufuk , Sen, Rajeev , Burkhardt, Jan‐Karl , Starke, Robert M. , Sekhar, Laligam N., Altschul, David , Haranhalli, Neil , McAvoy, Malia , Zeineddine, Hussein A. , Atallah, Elias , Rosenwasser, Robert H. , Stapleton, Christopher J. , Koch, Matthew J. , Srinivasan, Visish M. , Bulsara, Ketan R., Kim, Louis J. , Pukenas, Bryan, Smith, Edward R. , Alaraj, Ali , Patel, Aman B. , Notarianni, Christina , Lawton, Michael, Guthikonda, Bharat , Salim, Hamza , Riina, Howard , Dmytriw, Adam A , Gummadi, Sanjeev , Ataoglu, Cagdas , Essibayi, Muhammed Amir , Keles, Abdullah , Muram, Sandeep , Alwakaa, Omar , Mantziaris, Georgios , Park, Min S , Hanalioglu, Sahin , Erginoglu, Ufuk , Pöppe, Johannes , Griessenauer, Christoph J , Starke, Robert M , Levitt, Michael R , Altschul, David J , Haranhalli, Neil , Zeineddine, Hussein A , Atallah, Elias , Stapleton, Christopher , Koch, Matthew J , Srinivasan, Visish M , Chen, Peng R , Blackburn, Spiros , Bulsara, Ketan , Choudhri, Omar , Pukenas, Bryan , Smith, Edward , Alaraj, Ali , Patel, Aman B , Notarianni, Christina , Jabbour, Pascal , Musmar, Basel , Ogilvy, Christopher S , Tjoumakaris, Stavropoula , Kandregula, Sandeep , Dmytriw, Adam A. , Naamani, Kareem El , Abdelsalam, Ahmed , Kumbhare, Deepak , Essibayi, Muhammed Amir , Keleş, Abdullah , Tos, Salem M , Mantziaris, Georgios , Sen, Rajeev D., Griessenauer, Christoph J. , Sekhar, Laligam N. , Levitt, Michael R. , Abla, Adib A. , Gooch, Michael Reid , Kim, Louis J. , Choudhri, Omar , Pukenas, Bryan , Mosimann, Pascal J , Aziz‐Sultan, Mohammad Ali , Savardekar, Amey Rajan , Cuellar, Hugo , Morcos, Jacques J. , Jabbour, Pascal

Mayo Clinic

Radiology | October 21, 2025 | Volume: 317 | Issue: 1 | Pages: No page available

10.1148/radiol.250329 | PMID 41117652 Get It

Stereotactic radiosurgery was associated with a higher obliteration rate compared with embolization in patients with eloquent brain arteriovenous malformations, whereas there was no evidence of a difference in functional outcomes or complications after adjustment.
Targeting CDK12 disrupts estrogen-receptor chromatin recruitment and ER-MED1 transcription in advanced ER+ breast cancer
Ottaviani, Daniela , Ola, Mihaela , Hickey, Seán , Jagušt, Petra , Cosgrove, Nicola , Cocchiglia, Sinéad , Bane, Fiona T., Fallon, Ramón, Daly, Gordon, Hudson, Lance, Kalsi, Shannon, Shovlin, Stephen, Powell, Aoibhín , Bahl, Ash , Ainscow, Ed, Oesterreich, Steffi , Couch, Fergus J. , Hill, Arnold D., Varešlija, Damir , Allotta, Alessandra , Hickey, Seán , Jagust, Petra , Cosgrove, Nicola , Cocchiglia, Sinéad , Bane, Fiona , Fallon, Ramón , Daly, Gordon , Hegarty, Aisling , Hudson, Lance , Sheehan, Katherine , Kalsi, Shannon , Shovlin, Stephen , Powell, Aoibhín , Ainscow, Ed , Oesterreich, Steffi , Lee, Adrian V , Hill, Arnold D K , Varešlija, Damir , Young, Leonie , Chaibi, Yasmine Maati, Lee, Adrian V. , Couch, Fergus J.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | October 14, 2025 | Volume: 118 | Issue: 3 | Pages: 404-421

10.1093/jnci/djaf295 | PMID 41092317 Get It

Abstract Background Cyclin-dependent kinase 12 (CDK12) regulates general gene transcription elongation and plays multiple roles in RNA splicing, DNA damage-response, cell cycle, and genomic stability. However, transcriptional partners that guide CDK12-specific gene programs have not been identified. Genomic alterations in CDK12 have been observed in multiple cancers, exhibiting both pro-tumorigenic and tumor-suppressive functions, suggesting a context-dependent mechanism of action. Methods CDK12 copy number alterations and gene expression levels were analyzed in matched primary and brain metastatic patient tumors. Clinical significance was assessed by immunohistochemistry in a large cohort of primary breast cancer patient tumors. RNA sequencing, ChIP sequencing, and molecular studies were conducted to explore CDK12’s mechanism of action, and pharmacological studies were performed both in vitro and in vivo using models of advanced (endocrine-resistant and metastatic) estrogen receptor positive (ER+) disease. Results CDK12 amplifications and gene overexpression were observed in brain metastatic tumors. In ER+ primary patient tumors, high CDK12 protein expression was significantly associated with poor overall survival, particularly within the ER+/HER2-negative group. In ER+ endocrine resistant models, CDK12 regulated estrogen signaling pathways, with ER/MED1 identified as the master transcriptional complex directing CDK12-specific pro-tumorigenic gene programs. Pharmacological inhibition of CDK12 significantly reduced viability in endocrine resistant and metastatic cell and organoid models in vitro, and decreased metastatic spread in vivo. Conclusion This work describes a novel mechanism for CDK12, suggesting a potential vulnerability in ER+ breast cancer. These findings provide a basis for further investigation into the role of CDK12 inhibition as a therapeutic approach, particularly in advanced disease settings.
P11.14.A STEREOTACTIC RADIOSURGERY FOR OVARIAN CANCER BRAIN METASTASES: AN INTERNATIONAL RADIOSURGERY RESEARCH FOUNDATION RETROSPECTIVE STUDY
Mathieu, D, Billau, Mathilde Djeneba, Adam, Elizabeth , Iorio‐Morin, Christian , Liscak, R, Niranjan, A, Wei, Zheng , Lunsford, L. Dade , José, São, Scanlon, Samantha, Silverman, Joshua B., Mullen, Russell , Bernstein, Kenneth , Samanci, Yavuz, Düzkalır, Ali Haluk , Phuong, Christina , Sheehan, Jason , Pikis, Styllianos, Kosyakovsky, Jacob, Prasad, Rajendra , Cifarelli, Daniel T. , Icaza, Denisse Arteaga, Wegner, Rodney E. , Shepard, M J, Bowden, Greg , Wandrey, Narine , Rusthoven, Chad G. , Hintz, Eric , Schulder, Michael , Goenka, Anuj , Peterson, Jeffrey J., Mathieu, David , Hamel, Andréanne, Liscak, R, May, Jaromír , Niranjan, A, Wei, Z, Luy, Diego D. , Silverman, J, Kondziolka, Douglas , Peker, Selçuk , Samancı, Yavuz , Braunstein, Steve , Prasad, R N, Palmer, Joshua D. , Bailey, D, Zacharia, Brad E. , Cifarelli, Christopher P.

Mayo Clinic

Neuro-Oncology | October 3, 2025 | Volume: 27 | Issue: Supplement_3 | Pages: iii106-iii106

10.1093/neuonc/noaf193.353 Get It

Abstract BACKGROUND Ovarian cancer rarely metastasises to the brain, thus studies reporting the outcomes of affected patients are lacking. Stereotactic radiosurgery (SRS) is now the mainstay of management for patients with brain metastases (BM) from most primary sites, but little evidence of its efficacy in ovarian cancer is available. The current study was undertaken to provide guidance for SRS management using pooled data from multiple institutions. MATERIAL AND METHODS Centers participating in the IRRF (International Radiosurgery Research Foundation) were asked to provide outcome data for patients who had SRS for ovarian cancer brain metastases between 2020 and 2024 and at least one clinical and imaging follow-up after the procedure. Primary endpoints included survival from SRS, local tumor response according to RANO-BM criteria and occurrence of adverse radiation effects (ARE). Cox regression analyses were performed to identify variables impact each endpoint. RESULTS 128 patients had SRS for a total of 532 BM treated. Epithelial histology was the most common (91%). Median age at SRS was 62 years (IQR 56-70). Median KPS was 80% (IQR 80-90%) and 71.9% of patients had neurological symptoms at presentation. Other active systemic metastases were present in 41.4%. The median number of treated BM was 2 (IQR1-3) and the median cumulative treatment volume was 6 cc (IQR 2-12.9). The median margin dose was 18 Gy (IQR 16-20). At last follow-up, 19.5% of patients were still alive. The median overall survival (OS) after SRS was 27 months, and 6-, 12- and 24-month OS was 83.8%, 74.2% and 52.2%, respectively. Multivariate analyses revealed that increasing age at SRS (HR 1.02, p=0.05), active systemic metastases (HR 2, p=0.005) and increasing number of brain metastases (HR 1.05, p=0.04) were associated with worse survival, while repeating SRS (HR 0.4, p=0.002) led to improved survival. Local failure occurred in 12.8% of treated BM. Actuarial progression-free survival (PFS) at 6, 12 and 24 months was 92.3%, 86.6% and 70.3%, respectively. Only prior WBRT (HR 4.36, p=0.03) led to worse local control on multivariate analyses. New remote BM appeared in 49.5% of patients and 14.5% suffered from leptomeningeal dissemination. ARE were seen in 12.1% of BM but were symptomatic in only 3.2%. On multivariate analyses, prior SRS (HR 3.13, p=0.002) was associated with increased risk of ARE. CONCLUSION Ovarian cancer brain metastases can be safely and effectively managed with SRS as the primary treatment modality in most patients.
Stereotactic Radiosurgery Versus Observation in Small- and Medium-Sized Vestibular Schwannoma Patients With Normal Hearing: A Retrospective International Multicenter Study
Hajikarimloo, Bardia , Ishaque, Mariam , Samanci, Yavuz, Pelcher, Isabelle , Begley, Sabrina , Goenka, Anuj , Schulder, Michael , Tourigny, Jean-Nicolas, Hamel, Andréanne, Briggs, Robert G. , Yu, Cheng , Zada, Gabriel , Giannotta, Steven L. , Palque, Sarai, Kumar, Narendra , Rogowski, Brandon, Shepard, Matthew J., Vasconcellos, Fernando De Nigris , Bernstein, Kenneth , Sheehan, Jason P. , Johnson, Bryan A, Sheehan, Jason , Bin-Alamer, Othman , Tos, Salem M , Mantziaris, Georgios , Abou‐Al‐Shaar, Hussam , Peker, Selçuk , Samancı, Yavuz , Mathieu, David , Speckter, Herwin , Tripathi, Manjul , Kumar, Saurabh , Kaur, Rupinder , Johnson, Bryan A., Trifiletti, Daniel M. , Warnick, Ronald E. , Mashiach, Elad , Schnurman, Zane , Alzate, Juan Diego , Kondziolka, Douglas

Mayo Clinic

Neurosurgery | September 16, 2025 | Volume: 98 | Issue: 4 | Pages: 887-894

10.1227/neu.0000000000003734 | PMID 40956102 Get It

BACKGROUND AND OBJECTIVES: The therapeutic approach for small- and medium-sized vestibular schwannoma (VS) with normal hearing function remains controversial, with limited comparative data regarding hearing outcomes after stereotactic radiosurgery (SRS) or observation (OBS). We evaluated the serviceable hearing preservation, loss of American Academy of Otolaryngology-Head and Neck Surgery class A hearing, and tumor control (TC) across individuals with Koos grade I and II VSs and normal hearing at presentation who underwent SRS or OBS. METHODS: In this multicenter international study, we retrospectively analyzed the hearing, radiological, and neurological outcomes of patients who underwent SRS (SRS group) or OBS (OBS group). The cohorts were matched using propensity scores based on age, sex, tumor volume, pure-tone average, and speech discrimination score at a 1:1 ratio without replacement. RESULTS: After matching, each group comprised 57 patients. The median follow-up was 49 and 37 months for the SRS and the OBS groups, respectively ( P = .3). The 5- and 9-year serviceable hearing preservation rates in the SRS group were 76.2% and 42.4% vs 56.1% and 16.8% in the OBS group ( P = .17). Class A preservation occurred in 57.9% (33/57) of the SRS and 52.6% (30/57) of the OBS cohorts ( P = .70). Regarding the TC rates, SRS was associated with significantly higher TC rates ( P < .0001). CONCLUSION: We found that SRS is significantly superior regarding TC and provided noninferior hearing outcomes compared with OBS in VS patients with American Academy of Otolaryngology-Head and Neck Surgery class A hearing at presentation. Therefore, we suggest performing SRS in individuals with VS and normal hearing function.
Safety and efficacy of preoperative embolization in the treatment of brain arteriovenous malformations with perinidal aneurysms and single draining vein: a multicenter study with propensity score-weighting
Adeeb, Nimer , Abdalrazeq, Hammam , Salim, Hamza , Tjoumakaris, Stavropoula , Kandregula, Sandeep , Ogilvy, Christopher S. , Sheehan, Jason , Aslan, Assala , Patel, Pious D. , Lan, Matthews , Baldassari, Michael P. , Koduri, Sravanthi , Atallah, Elias , Zeineddine, Hussein A. , Pontarelli, Mary-Katharine , Naamani, Kareem El, Ironside, Natasha , Gummadi, Sanjeev, Başkaya, Mustafa K. , Ataoglu, Cagdas , Mccarthy, Finn, Sanchez‐Forteza, Anthony , Essibayi, Muhammed Amir , Muram, Sandeep , Sconzo, Daniel , Riina, Howard A. , Rezai, Arwin, Alwakaa, Omar , Erginoğlu, Ufuk , Sen, Rajeev , Devia, Diego A., Perez-Mendez, Wilfran, Puentes, Juan C. , Spiotta, Alejandro M , Puri, Ajit S , Singh, Jasmeet, Burkhardt, Jan Karl, Starke, Robert M., Sekhar, Laligam N., Haranhalli, Neil , McAvoy, Malia , Eltiti, Marah, Abushehab, Abdallah, Foreman, Paul M. , Zaidat, Osama O. , Ruppert-Gomez, Marcella , Stapleton, Christopher J. , Koch, Matthew J. , Srinivasan, Visish M, Alshahrani, Rabab, Gooch, M Reid, Rosenwasser, Robert H. , Bulsara, Ketan R., Kan, Peter , Kim, Louis J. , Pukenas, Bryan , Li, Yan-Lin , Alaraj, Ali , Fuschi, Maurizio , Patel, Aman B. , Notarianni, Christina , Cuellar, Hugo H, Lawton, Michael T., Guthikonda, Bharat , Jabbour, Pascal , Salim, Hamza , Tjoumakaris, Stavropoula , Kandregula, Sandeep , Ogilvy, Christopher S , Dmytriw, Adam A , Aslan, Assala , Essibayi, Muhammed Amir , Alwakaa, Omar , Griessenauer, Christoph J , Abo Kasem, Rahim , Spiotta, Alejandro M , Levitt, Michael R , Altschul, David J , Shakir, Hakeem J , Zaidat, Osama O , Stapleton, Christopher , Koch, Matthew J , Chen, Peng R , Kan, Peter , Choudhri, Omar , Alaraj, Ali , Guthikonda, Bharat , Jabbour, Pascal , Erginoglu, Ufuk , Li, Yan-Lin , Burkhardt, Jan‐Karl , Musmar, Basel , Roy, Joanna M. , Kondziolka, Douglas , Dmytriw, Adam A. , Abou‐Al‐Shaar, Hussam , Naamani, Kareem El, Abdelsalam, Ahmed , Kumbhare, Deepak , Mccarthy, Finn, Keleş, Abdullah , Tos, Salem M , Mantziaris, Georgios , Park, Min S, Hanalıoğlu, Şahin , Pöppe, Johannes , Sen, Rajeev D, Griessenauer, Christoph J. , Ocampo-Navia, María Isabel , Kasem, Rahim Abo , Kühn, Anna Luisa , Sekhar, Laligam N. , Levitt, Michael R. , Altschul, David , Almajali, Mohammad , See, Alfred P. , Abla, Adib A. , Patel, Aashay , Nguyen, Andrew , Srinivasan, Visish M. , Blackburn, Spiros , Gooch, Michael Reid , Kim, Louis J. , Choudhri, Omar , Simonato, Davide , Savardekar, Amey Rajan , Lawton, Michael T. , Morcos, Jacques J.

Mayo Clinic

Journal of NeuroInterventional Surgery | August 22, 2025 | Volume: 18 | Issue: 8 | Pages: 1765-1772

10.1136/jnis-2025-023873 | PMID 40846482 Get It

Background and objectives Arteriovenous malformations (AVMs) with perinidal aneurysms and single draining vein are associated with an elevated risk of rupture and increased procedural complexity. The role of preoperative embolization in this high-risk anatomical subset remains unclear. This study aimed to evaluate the safety and efficacy of microsurgery with preoperative embolization, compared with microsurgery alone in patients with such AVMs. Methods We conducted a multicenter retrospective analysis of an AVM registry from the MISTA (Multicenter International Study for Treatment of Brain AVMs) consortium and included AVMs with perinidal aneurysms and a single draining vein. Baseline characteristics, angiographic outcomes, functional outcomes, and complication rates were compared. Propensity score weighting (PSW) using the covariate balancing method was applied to adjust for baseline differences. Results Out of a total of 1919 patients, 65 met the inclusion criteria; 45 patients underwent preoperative embolization followed by microsurgery, and 20 underwent microsurgery alone. After adjustment, complete obliteration rates were similar between groups (OR 0.87, 95% CI 0.04 to 16.33, P=0.92), as were rates of functional independence at discharge and follow-up. Overall complication, symptomatic complication, and mortality rates did not differ significantly between groups. However, permanent complications were significantly lower in patients with preoperative embolization (OR 0.06, 95% CI 0.004 to 0.84, P=0.03). Discussion In patients with AVMs featuring perinidal aneurysms and single draining vein, preoperative embolization followed by microsurgery was associated with fewer permanent complications and no increase in adverse outcomes compared with microsurgery alone. However, given the small number of events, this finding should be interpreted cautiously.
Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines for the Role of Radiosurgery for Patients With Functioning Pituitary Adenomas
Green, Sheryl , Lehrer, Eric J. , Sheehan, Jason , Cifarelli, Christopher P. , Recinos, Pablo F. , Ziu, Mateo , Ormond, David Ryan , Germano, Isabelle M.

Mayo Clinic

Neurosurgery | August 15, 2025 | Volume: 97 | Issue: 3S | Pages: S36-S43

10.1227/neu.0000000000003582 | PMID 40815129 Get It

BACKGROUND: Patients with functioning pituitary adenomas (FPA) require a multidisciplinary team-based approach to select best medical, surgical, and radiation treatments, including stereotactic radiosurgery (SRS). OBJECTIVE: The aim of this study was to provide evidence-based recommendations on the use of SRS for adult patients with FPA. METHODS: PubMed and Embase were searched from data base inception to June 8, 2021. Full-text articles were then screened using published exclusion/inclusion criteria. Evidence tables were developing based on data extraction from the full-text reviews, and evidence-based recommendations were finalized. RESULTS: Of the total 1842 abstracts pertinent to this topic, 343 full articles met eligibility. Of these, 21 met entry criteria and were included in the evidence tables. The provided Class III evidence supported 2 Level III recommendations: 1. SRS, hypofractionated SRS, fractionated (>5 fractions) radiotherapy, and conventional radiation therapy provide excellent radiographic control with variable hormonal reduction and endocrine remission rates. For SRS and fractionated radiotherapy hormonal reduction may continue for up to 10 years after treatment. 2. Clinicians may continue to administer endocrine suppressive medical treatment before SRS as this may not affect radiographic control. CONCLUSION: This systematic review provides evidence-based recommendations to guide providers caring for adult patients with FPA when making decisions pertinent to radiosurgery. The CNS Guidelines Committee will continue to pursue timely updates to further improve the care of patients with this diagnosis.
Outcome Evaluation of Volume-Staged Stereotactic Radiosurgery for Cerebral Arteriovenous Malformations
Mantziaris, Georgios , Hajikarimloo, Bardia , Tos, Salem M , Pikis, Stylianos , Chan, Jason W., Sneed, Penny K. , McDermott, Michael W. , Seymour, Zachary , Grills, Inga S., Reda, Wael A. , Tawadros, Sameh R. , Emad, Reem M. , Lunsford, L. Dade , Niranjan, Ajay , Lee, Cheng‐Chia , Sheehan, Darrah, Sheehan, Kimball , Chytka, Tomáš , Meng, Ying , Moreno, Nuria Martínez , Álvarez, Roberto Martínez , Hallan, David R , Fritch, Chanju , Jareczek, Frank, Sciscent, Bao Y. , Carrier, Louis, Abdelsalam, Ahmed Ragab , Starke, Robert M. , Benjamin, Carolina , Singh, S.P., Lazo, Erwin , Esquenazi, Yoshua , Blanco, Angel I., Picozzi, Piero, Lanterna, Luigi Alberto Andrea, Bowden, Greg , Peterson, Jennifer , Chiang, Veronica , Ishaque, Mariam , Sheehan, Jason P. , Bin-Alamer, Othman , Mantziaris, Georgios , Nabeel, Ahmed M. , Reda, Wael A. , Abdelkarim, Khaled , El-Shehaby, Amr M. N. , Bin-Alamer, Othman , Peker, Selçuk , Samancı, Yavuz , Yang, Huai‐Che , Liščák, Roman , Alzate, Juan Diego , Kondziolka, Douglas , Jareczek, Frank, Mathieu, David , Carrier, Louis, Almeida, Timóteo , Tripathi, Manjul , Speckter, Herwin , Chen, Ching‐Jen , Becerril‐Gaitan, Andrea , Amsbaugh, Mark J. , Upadhyay, Rituraj , Palmer, Joshua D. , Franzini, Andrea , Picozzi, Piero , Warnick, Ronald E. , Protopapa, Maria

Mayo Clinic

Neurosurgery | August 11, 2025 | Volume: 98 | Issue: 1 | Pages: 174-184

10.1227/neu.0000000000003682 | PMID 40788018 Get It

BACKGROUND AND OBJECTIVES: Single-session stereotactic radiosurgery (SRS) has limited role for large arteriovenous malformations (AVM). Volume-staged SRS (VS-SRS) is used to optimize outcomes, but studies reporting results are limited. METHODS: This multicenter retrospective cohort of 378 patients from 21 centers reports results of VS-SRS for the entire AVM nidus. We report favorable outcome, obliteration, hemorrhage, and permanent symptomatic adverse radiation effect rates. RESULTS: The median age was 31 years (IQR: 19-44) at the first volume stage, with patients treated in 2–4 stages. The median total nidus volume was 21 cm 3 (IQR: 13.9-30.1 cm 3 ), and a median prescription dose of 17 Gy (IQR: 16-18 Gy) was used. The median radiographic and clinical follow-up were 48 and 55 months, respectively. Seventy-seven patients (20.4%) had a favorable outcome, with the 3-year and 5-year rates being 3.9% and 18%, respectively. 127 patients (33.6%) achieved obliteration, with the 3-year and 5-year rates being 6.8% and 26%, respectively. Obliteration rates of AVMs <15 cm 3 were 81% and 31%, respectively. The latency period hemorrhage incidence rate was 3.02 cases per 100 patient-years; 52 patients (13.8%) had a bleed. Seventy-two patients (19%) had symptomatic adverse radiation effect; in 38 patients (10.1%), these were permanent. Total nidus volume, prescription dose at first stage, diffuse nidus, and prior hemorrhage were all independent affecting outcome rates. CONCLUSION: VS-SRS can be used to treat large AVMs as a standalone treatment. Obliteration rates and favorable outcomes are lower than that with smaller AVMs, and repeat treatment is often required. Optimizing treatment plans, by increasing prescription doses, reducing treatment volume at each stage, and increasing the number of stages, may lead to better outcomes.
O-039 Consortium for dural arteriovenous fistula outcomes research (CONDOR): endovascular treatment of tentorial dural arteriovenous fistulae
Hallak, Hana , Chalouhi, Nohra , Gross, Bradley A. , Satomi, Junichiro, Levitt, M, Sheehan, Jason , Zipfel, Gregory J. , Chatterjee, A, Gross, Bradley , Dijk, J Van, Bulters, Diederik , Hayakawa, M. , Lanzino, Giuseppe , Levitt, M, Alaraj, Ali , Osbun, Joshua W

Mayo Clinic

SNIS 22nd annual meeting oral abstracts | July 14, 2025 | Volume: No volume available | Issue: No issue available | Pages: A33-A34

10.1136/jnis-2025-snis.39 Get It

Multicenter Retrospective Study of Stereotactic Radiosurgery for Gynecological Cancer Brain Metastases
Billau, Mathilde Djeneba, Hamel, Andréanne, Tourigny, Jean-Nicolas, Iorio‐Morin, Christian , Niranjan, Ajay , Wei, Zhishuo , Lunsford, L. Dade , Jose, Shalini, Scanlon, Sydney, Mullen, Reed, Bernstein, Kenneth , Phuong, Christina , Sheehan, Jason P. , Pikis, Stylianos , Kosyakovsky, Jacob, Prasad, Rahul N. , Icaza, Denisse Arteaga, Cifarelli, Daniel T. , Wegner, Rodney E. , Shepard, Matthew J., Bowden, Gregory, Wandrey, Narine , Rusthoven, Chad G. , Hintz, Eric , Schulder, Michael , Goenka, Anuj , Peterson, Jennifer , Mathieu, David , Liščák, Roman , May, Jaromír , Luy, Diego D. , Silverman, Joshua S. , Kondziolka, Douglas , Peker, Selçuk , Samancı, Yavuz , Braunstein, Steve , Palmer, Joshua D. , Bailey, David, Zacharia, Brad E. , Cifarelli, Christopher P. , Mathieu, David

Mayo Clinic

Neurosurgery | July 7, 2025 | Volume: 98 | Issue: 1 | Pages: 194-203

10.1227/neu.0000000000003609 | PMID 40622139 Get It

BACKGROUND AND OBJECTIVES: Gynecological cancers represent 10% to 15% of cancers in women, but brain metastases (BM) are uncommon, with limited evidence regarding their management. This study investigates the role of stereotactic radiosurgery (SRS) for BM from primary gynecological cancers. METHODS: Institutions of the International Radiosurgery Research Foundation participated in this study. Inclusion criteria required histological diagnosis of epithelial ovarian, cervical, or endometrial cancer, SRS between 2000 and 2020, and at least 1 imaging or clinical follow-up. RESULTS: A total of 276 patients having SRS for 977 BM were included. Median age at SRS was 62 years (IQR, 55-70). Primary cancer origin was ovarian in 128 (46%), cervical in 43 (16%), and endometrial in 105 patients (38%). Median Karnofsky Performance Scale was 80%, and systemic disease was active in 124 (45%) of patients. A median of 1 metastasis was treated (IQR, 1-3) per patient. Median individual metastasis volume was 0.27 cc (IQR, 0.05-1.59 cc). The majority (91%) received single-fraction SRS, using a median margin dose of 18 Gy (IQR, 16-20 Gy). Actuarial overall survival was 77%, 65%, and 44% at 6, 12, and 24 months, respectively. Predictors of worsened survival included older age, cervical and endometrial primary, previous whole-brain radiation therapy (WBRT), active systemic disease, worsened Karnofsky Performance Scale, absence of subsequent surgery, and increasing number of BM. Actuarial local control was 94% at 6 months, 89% at 12 months, and 78% at 24 months. Previous SRS or WBRT, tumor bed treatment, and cervical histology increased the risk of local failure. New remote BM and leptomeningeal dissemination occurred in 44% and 11% of patients, respectively. Adverse radiation effects (ARE) occurred in 13% of cases but were symptomatic in only 3%. Previous WBRT or SRS and increased tumor diameter increased the risk of ARE. CONCLUSION: SRS is an effective management for BM from gynecological cancers with low risks of symptomatic ARE.